Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brenda F Baker

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Biochemical Pharmacology|August 18, 2020
Antisense drug discovery and development technology considered in a pharmacological contextStanley T Crooke, Xue-Hai Liang, Rosanne M Crooke, et al.
Nucleic Acid Therapeutics|July 9, 2021
Improvements in the Tolerability Profile of 2'-<i>O</i>-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other MethodsWesley Partridge, Shuting Xia, T Jesse Kwoh, et al.
Journal of the American Heart Association|March 15, 2014
Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteersJoann D Flaim, John S Grundy, Brenda F Baker, et al.
Nucleic Acid Therapeutics|December 1, 2022
Integrated Assessment of Phase 2 Data on GalNAc<sub>3</sub>-Conjugated 2'-<i>O</i>-Methoxyethyl-Modified Antisense OligonucleotidesBrenda F Baker, Shuting Xia, Wesley Partridge, et al.
The Journal of Biological Chemistry|December 26, 2002
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysisTimothy A Vickers, Seongjoon Koo, C Frank Bennett, et al.
Clinical and Translational Science|January 11, 2023
Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse eventsWesley Partridge, Sebastien A Burel, Annie Ferng, et al.
Nucleic Acid Therapeutics|August 17, 2022
Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear CellsSebastien A Burel, Todd Machemer, Brenda F Baker, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trialRohit Loomba, Erin Morgan, Lynnetta Watts, et al.
Nucleic Acid Therapeutics|January 16, 2024
Safety and Tolerability of GalNAc<sub>3</sub>-Conjugated Antisense Drugs Compared to the Same-Sequence 2'-<i>O</i>-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial DataBrenda F Baker, Shuting Xia, Wesley Partridge, et al.
Molecular Pharmacology|August 24, 2004
Effects of antisense oligonucleotide-mediated depletion of tumor necrosis factor (TNF) receptor 1-associated death domain protein on TNF-induced gene expressionAndrew M Siwkowski, Lisa A Madge, Seongjoon Koo, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Biochemical Pharmacology|August 18, 2020
Antisense drug discovery and development technology considered in a pharmacological contextStanley T Crooke, Xue-Hai Liang, Rosanne M Crooke, et al.
Nucleic Acid Therapeutics|July 9, 2021
Improvements in the Tolerability Profile of 2'-<i>O</i>-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other MethodsWesley Partridge, Shuting Xia, T Jesse Kwoh, et al.
Journal of the American Heart Association|March 15, 2014
Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteersJoann D Flaim, John S Grundy, Brenda F Baker, et al.
Nucleic Acid Therapeutics|December 1, 2022
Integrated Assessment of Phase 2 Data on GalNAc<sub>3</sub>-Conjugated 2'-<i>O</i>-Methoxyethyl-Modified Antisense OligonucleotidesBrenda F Baker, Shuting Xia, Wesley Partridge, et al.
The Journal of Biological Chemistry|December 26, 2002
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysisTimothy A Vickers, Seongjoon Koo, C Frank Bennett, et al.
Clinical and Translational Science|January 11, 2023
Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse eventsWesley Partridge, Sebastien A Burel, Annie Ferng, et al.
Nucleic Acid Therapeutics|August 17, 2022
Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear CellsSebastien A Burel, Todd Machemer, Brenda F Baker, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trialRohit Loomba, Erin Morgan, Lynnetta Watts, et al.
Nucleic Acid Therapeutics|January 16, 2024
Safety and Tolerability of GalNAc<sub>3</sub>-Conjugated Antisense Drugs Compared to the Same-Sequence 2'-<i>O</i>-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial DataBrenda F Baker, Shuting Xia, Wesley Partridge, et al.
Molecular Pharmacology|August 24, 2004
Effects of antisense oligonucleotide-mediated depletion of tumor necrosis factor (TNF) receptor 1-associated death domain protein on TNF-induced gene expressionAndrew M Siwkowski, Lisa A Madge, Seongjoon Koo, et al.
Pageof 6